Stock Track | United Therapeutics Plummets 5.06% as Q2 Earnings Miss Estimates

Stock Track

Jul 31, 2025

United Therapeutics (UTHR) saw its stock price plummet by 5.06% in intraday trading on Wednesday following the release of its second-quarter 2025 financial results. The biopharmaceutical company's earnings and revenue fell short of Wall Street expectations, disappointing investors and triggering a sell-off.

The company reported earnings per share (EPS) of $6.41, missing the FactSet consensus estimate of $6.94. While this represents an increase from $5.85 in the same quarter last year, it failed to meet market expectations. Revenue for the quarter came in at $798.6 million, up 11.7% year-over-year but falling short of the analyst consensus of $804.3 million.

Despite reporting record total revenue and highlighting strong performance in key products like Tyvaso DPI, which saw 22% growth over Q2 2024, investors seemed to focus on the earnings miss. The company's announcement of a new $1 billion share repurchase program, expiring in March 2026, did little to offset the negative sentiment. As United Therapeutics continues to invest in its pipeline, including ongoing Phase 3 studies for Nebulized Tyvaso and ralinepag, investors will be closely watching for updates on these potential growth drivers in the coming quarters.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1124289342"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1124289342\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1124289342?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-31 02:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1124289342","market":"us","top_or_hot":-1,"title":"Stock Track | United Therapeutics Plummets 5.06% as Q2 Earnings Miss Estimates","media":"Stock Track","content":"<p>United Therapeutics (UTHR) saw its stock price plummet by 5.06% in intraday trading on Wednesday following the release of its second-quarter 2025 financial results. The biopharmaceutical company's earnings and revenue fell short of Wall Street expectations, disappointing investors and triggering a sell-off.</p>\n\n<p>The company reported earnings per share (EPS) of $6.41, missing the FactSet consensus estimate of $6.94. While this represents an increase from $5.85 in the same quarter last year, it failed to meet market expectations. Revenue for the quarter came in at $798.6 million, up 11.7% year-over-year but falling short of the analyst consensus of $804.3 million.</p>\n\n<p>Despite reporting record total revenue and highlighting strong performance in key products like Tyvaso DPI, which saw 22% growth over Q2 2024, investors seemed to focus on the earnings miss. The company's announcement of a new $1 billion share repurchase program, expiring in March 2026, did little to offset the negative sentiment. As United Therapeutics continues to invest in its pipeline, including ongoing Phase 3 studies for Nebulized Tyvaso and ralinepag, investors will be closely watching for updates on these potential growth drivers in the coming quarters.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | United Therapeutics Plummets 5.06% as Q2 Earnings Miss Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | United Therapeutics Plummets 5.06% as Q2 Earnings Miss Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-07-31 02:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>United Therapeutics (UTHR) saw its stock price plummet by 5.06% in intraday trading on Wednesday following the release of its second-quarter 2025 financial results. The biopharmaceutical company's earnings and revenue fell short of Wall Street expectations, disappointing investors and triggering a sell-off.</p>\n\n<p>The company reported earnings per share (EPS) of $6.41, missing the FactSet consensus estimate of $6.94. While this represents an increase from $5.85 in the same quarter last year, it failed to meet market expectations. Revenue for the quarter came in at $798.6 million, up 11.7% year-over-year but falling short of the analyst consensus of $804.3 million.</p>\n\n<p>Despite reporting record total revenue and highlighting strong performance in key products like Tyvaso DPI, which saw 22% growth over Q2 2024, investors seemed to focus on the earnings miss. The company's announcement of a new $1 billion share repurchase program, expiring in March 2026, did little to offset the negative sentiment. As United Therapeutics continues to invest in its pipeline, including ongoing Phase 3 studies for Nebulized Tyvaso and ralinepag, investors will be closely watching for updates on these potential growth drivers in the coming quarters.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"UTHR","symbol_name":"美国联合医疗","start_time":0,"source_url":"","article_id":"1124289342","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1124289342","pubTimestamp":1753900248,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"United Therapeutics (UTHR) saw its stock price plummet by 5.06% in intraday trading on Wednesday following the release of its second-quarter 2025 financial results. The biopharmaceutical company's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"UTHR":"美国联合医疗"},"translate_title":"个股追踪|United Therapeutics暴跌5.06%Q2盈利不及预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"UTHR":1},"content_text":"United Therapeutics (UTHR) saw its stock price plummet by 5.06% in intraday trading on Wednesday following the release of its second-quarter 2025 financial results. The biopharmaceutical company's earnings and revenue fell short of Wall Street expectations, disappointing investors and triggering a sell-off.\nThe company reported earnings per share (EPS) of $6.41, missing the FactSet consensus estimate of $6.94. While this represents an increase from $5.85 in the same quarter last year, it failed to meet market expectations. Revenue for the quarter came in at $798.6 million, up 11.7% year-over-year but falling short of the analyst consensus of $804.3 million.\nDespite reporting record total revenue and highlighting strong performance in key products like Tyvaso DPI, which saw 22% growth over Q2 2024, investors seemed to focus on the earnings miss. The company's announcement of a new $1 billion share repurchase program, expiring in March 2026, did little to offset the negative sentiment. As United Therapeutics continues to invest in its pipeline, including ongoing Phase 3 studies for Nebulized Tyvaso and ralinepag, investors will be closely watching for updates on these potential growth drivers in the coming quarters.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}